ORBIMED ADVISORS LLC
Registered adviserReports for
ORBIMED CAPITAL LLC
Filing Date
Global Rank
#869
/ 8,818
▼ 53
Top Industry
Biotechnology
72.2%
Period ended 4 months ago
Filed Aug 14, 2026 · 2mo
26 quarters · since Mar 2020
Regulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Holder type
Registered adviser
Form ADV roster, Oct 1, 2026
Regulatory AUM
$20,607,970,000
Main clients
Pooled investment vehicles
(100% of AUM)
Private funds
24 funds
· Other private funds
Focus by fund count, roster of Oct 1, 2026
$18,969,246,000 gross assets
LEI
57G4FX4JA0RP0CHYJ782
Private funds on Schedule D 7.B.(1)
As filed Mar 27, 2024; SEC's bulk Form ADV archive ends with 2024 filings.
$15,389,687,000 gross assets in 22 funds
Other private funds
$10,636,349,000
(13)
Private equity funds
$3,088,662,000
(3)
Hedge funds
$1,664,676,000
(6)
Form ADV history
Monthly rosters from Dec 2019; each row is a run with the same figures, newest first.
| Rosters | Regulatory AUM | Main clients |
|---|---|---|
| Sep 2026 to Oct 2026 | $20,607,970,000 | Pooled investment vehicles (100%) |
| Apr 2026 to Aug 2026 | $20,607,970,000 | Pooled investment vehicles (100%) |
| Mar 2026 | $17,339,330,000 | Pooled investment vehicles (100%) |
| Apr 2025 to Feb 2026 | $17,339,330,000 | Pooled investment vehicles (100%) |
| Apr 2024 to Mar 2025 | $18,211,070,000 | Pooled investment vehicles (100%) |
| May 2023 to Mar 2024 | $18,277,550,000 | Pooled investment vehicles (100%) |
5 earlier changes not shown.
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Style
Diversified active
Top 10 weight 43.1%, 29.1 effective positions, active share 95.4% against the Russell 2000 as of 2026-06-30; it meets none of the index-like, systematic-like or concentrated tests
Turnover
Medium turnover
51.3% over the last four quarters (30% to under 100%)
Horizon
Horizon unknown
The value-weighted holding period is at least 11.1 quarters, but 8.7% of the book was already held when coverage starts
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 95.4%; sector active share 90.9% against the combined 13F book's sector weights.
Over time 26 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
117 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
12.2%
+2.1 pts
Top 5
31.8%
+0.8 pts
Top 10
42.3%
−2.2 pts
HHI
331
Diversified+19
Portfolio Trend
26 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 99.1% | $5,124,541,261 |
| Unclassified | 0.9% | $47,475,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
25 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| SVRA | Savara Inc | +3,324,900 | 3,959,900 | $24,392,984 | |
| PRLD | Prelude Therapeutics Inc | +2,815,315 | 13,724,571 | $73,151,963 | |
| QTTB | Q32 Bio Inc. | +1,875,000 | 4,127,987 | $52,590,554 | |
| COGT | Cogent Biosciences, Inc. | +1,359,200 | 1,681,300 | $65,066,310 | |
| GPCR | Structure Therapeutics Inc. | +733,997 | 2,209,400 | $118,578,498 | |
| TRAW | Traws Pharma, Inc. | +597,729 | 1,203,260 | $1,010,738 | |
| SNDX | Syndax Pharmaceuticals Inc | +579,700 | 1,542,000 | $33,708,120 | |
| IMA | ImageneBio, Inc. | +530,713 | 909,269 | $5,364,687 | |
| — | +450,500 | 797,500 | $4,202,825 | ||
| LFST | LifeStance Health Group, Inc. | +447,400 | 947,400 | $10,146,654 | |
| BCRX | Biocryst Pharmaceuticals Inc | +426,800 | 1,852,000 | $18,520,000 | |
| — | +380,750 | 1,577,705 | $33,526,231 | ||
| LXEO | Lexeo Therapeutics, Inc. | +345,400 | 3,947,850 | $18,377,241 | |
| DYN | Dyne Therapeutics, Inc. | +317,800 | 3,235,684 | $71,864,541 | |
| AZN | Astrazeneca PLC | +245,500 | 915,700 | $173,635,034 | |
| KNSA | Kiniksa Pharmaceuticals International, plc | +240,001 | 420,600 | $26,897,370 | |
| NKTR | Nektar Therapeutics | +190,346 | 465,346 | $32,485,804 | |
| PVLA | Palvella Therapeutics, Inc. | +157,760 | 292,360 | $44,678,455 | |
| GH | Guardant Health, Inc. | +148,500 | 583,700 | $87,572,511 | |
| ANRO | Alto Neuroscience, Inc. | +90,352 | 257,852 | $6,804,714 | |
| ABVX | Abivax S.A. | +80,822 | 546,522 | $72,829,521 | |
| ASND | Ascendis Pharma A/S | +62,479 | 244,456 | $65,201,304 | |
| PRAX | Praxis Precision Medicines, Inc. | +57,600 | 230,100 | $77,035,179 | |
| MLYS | Mineralys Therapeutics, Inc. | +57,400 | 2,110,300 | $56,935,894 | |
| DRUG | Bright Minds Biosciences Inc. | +53,000 | 93,000 | $6,528,600 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
25 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | −1,182,906 | 6,776,632 | $343,914,074 | |
| RLMD | Relmada Therapeutics, Inc. | −1,084,669 | 3,631,195 | $25,127,869 | |
| TRVI | Trevi Therapeutics, Inc. | −1,024,107 | 1,430,293 | $26,674,964 | |
| SION | Sionna Therapeutics, Inc. | −974,825 | 2,555,877 | $112,433,029 | |
| BSX | Boston Scientific Corp | −898,900 | 1,483,200 | $63,302,976 | |
| IRON | Disc Medicine, Inc. | −710,015 | 357,535 | $26,150,109 | |
| ORIC | Oric Pharmaceuticals, Inc. | −678,929 | 2,015,000 | $21,822,450 | |
| NPCE | NeuroPace Inc | −591,402 | 1,505,125 | $23,916,436 | |
| HELP | Helus Pharma Inc. | −561,443 | 3,271,400 | $21,623,954 | |
| BCAX | Bicara Therapeutics Inc. | −476,200 | 191,100 | $5,673,759 | |
| JANX | Janux Therapeutics, Inc. | −458,900 | 524,700 | $8,059,392 | |
| DFTX | Definium Therapeutics, Inc. | −438,600 | 365,400 | $17,188,416 | |
| EW | Edwards Lifesciences Corp | −395,700 | 834,900 | $75,525,054 | |
| QURE | uniQure N.V. | −328,663 | 1,807,486 | $83,252,805 | |
| WHWK | Whitehawk Therapeutics, Inc. | −231,704 | 3,934,296 | $18,019,075 | |
| MBX | MBX Biosciences, Inc. | −209,151 | 3,428,736 | $189,266,227 | |
| URGN | UroGen Pharma Ltd. | −199,300 | 676,187 | $24,883,681 | |
| ACET | Adicet Bio, Inc. | −183,157 | 844,787 | $7,298,959 | |
| XENE | Xenon Pharmaceuticals Inc. | −167,500 | 892,471 | $53,869,549 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | −102,000 | 17,000 | $5,117,510 | |
| AXSM | Axsome Therapeutics, Inc. | −96,343 | 117,578 | $28,779,567 | |
| STRO | Sutro Biopharma, Inc. | −57,200 | 743,944 | $24,698,940 | |
| ISRG | Intuitive Surgical Inc | −50,800 | 157,900 | $62,793,672 | |
| ARGX | Argenx SE | −44,020 | 92,880 | $86,171,277 | |
| SYK | Stryker Corp | −23,400 | 159,100 | $50,091,044 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
25 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| UNH | Unitedhealth Group Inc | 161,100 | $66,957,993 | |
| HUM | Humana Inc | 164,100 | $65,183,802 | |
| ODTX | Odyssey Therapeutics, Inc. | 3,001,198 | $56,152,414 | |
| ARQT | Arcutis Biotherapeutics, Inc. | 2,042,000 | $53,541,240 | |
| WST | West Pharmaceutical Services Inc | 70,600 | $25,345,400 | |
| AURA | Aura Biosciences, Inc. | 3,333,333 | $23,666,664 | |
| SYRE | Spyre Therapeutics, Inc. | 186,145 | $16,525,953 | |
| WAT | Waters Corp | 40,300 | $15,114,112 | |
| MNPR | Monopar Therapeutics | 157,423 | $14,575,795 | |
| TVTX | Travere Therapeutics, Inc. | 253,000 | $14,372,930 | |
| TSHA | Taysha Gene Therapies, Inc. | 2,000,000 | $13,620,000 | |
| DNTH | Dianthus Therapeutics, Inc. | 115,000 | $11,210,200 | |
| SPRB | Spruce Biosciences, Inc. | 200,000 | $10,800,000 | |
| ERAS | Erasca, Inc. | 495,900 | $9,084,888 | |
| TARA | Protara Therapeutics, Inc. | 2,220,000 | $8,480,400 | |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 1,390,576 | $6,744,293 | |
| XLO | Xilio Therapeutics, Inc. | 592,300 | $5,674,234 | |
| NMRA | Neumora Therapeutics, Inc. | 2,139,882 | $3,637,799 | |
| ACAD | Acadia Pharmaceuticals Inc | 137,000 | $3,466,100 | |
| AMLX | Amylyx Pharmaceuticals, Inc. | 183,400 | $3,293,864 | |
| TYRA | Tyra Biosciences, Inc. | 102,000 | $3,257,880 | |
| RAPP | Rapport Therapeutics, Inc. | 76,616 | $3,192,588 | |
| AGMB | AgomAb Therapeutics NV | 192,740 | $2,501,765 | |
| TARS | Tarsus Pharmaceuticals, Inc. | 35,581 | $2,239,468 | |
| ACRS | Aclaris Therapeutics, Inc. | 421,500 | $2,229,735 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
19 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| PFE | Pfizer Inc | 1,946,500 | $54,657,720 | |
| DHR | Danaher Corp | 265,800 | $50,395,680 | |
| — | 10,570,300 | $28,962,622 | ||
| BTSG | BrightSpring Health Services, Inc. | 497,800 | $21,211,258 | |
| AMGN | Amgen Inc | 39,900 | $14,038,815 | |
| ALHC | Alignment Healthcare, Inc. | 791,000 | $13,937,420 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 14,700 | $11,357,808 | |
| CARL | Carlsmed, Inc. | 1,252,600 | $11,336,030 | |
| GILD | Gilead Sciences, Inc. | 59,600 | $8,306,452 | |
| HRTX | Heron Therapeutics, Inc. | 9,816,940 | $7,853,552 | |
| AVTX | Avalo Therapeutics, Inc. | 475,165 | $7,094,213 | |
| CMPS | COMPASS Pathways plc | 1,150,646 | $6,363,072 | |
| ADCT | ADC Therapeutics SA | 1,318,026 | $4,942,597 | |
| CGEM | Cullinan Therapeutics, Inc. | 243,006 | $3,453,115 | |
| JBIO | Jade Biosciences, Inc. | 185,011 | $2,599,404 | |
| CCCC | C4 Therapeutics, Inc. | 856,353 | $2,252,208 | |
| RCEL | AVITA Medical, Inc. | 544,895 | $2,016,111 | |
| — | 94,400 | $1,900,272 | ||
| VTGN | Vistagen Therapeutics, Inc. | 3,060,000 | $1,744,200 | |
| No positions match the current search. | ||||
117 tracked positions ·
$5,172,016,261 total
· filing declares
129 positions · $5,396,779,685
· as of Jun 30, 2026
Showing 1–50
of 117 positions by value
· page 1 of 3
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| EWTX |
Edgewise Therapeutics, Inc.
Healthcare
|
Held | 15,518,492 | $630,516,329 | 12.19% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Reduced | 6,776,632 | $343,914,074 | 6.65% | |
| LLY |
ELI LILLY & Co
Healthcare
|
Added | 257,900 | $309,333,022 | 5.98% | |
| MBX |
MBX Biosciences, Inc.
Healthcare
|
Reduced | 3,428,736 | $189,266,227 | 3.66% | |
| AZN |
Astrazeneca PLC
Healthcare
|
Added | 915,700 | $173,635,034 | 3.36% | |
| GPCR |
Structure Therapeutics Inc.
Healthcare
|
Added | 2,209,400 | $118,578,498 | 2.29% | |
| SION |
Sionna Therapeutics, Inc.
Healthcare
|
Reduced | 2,555,877 | $112,433,029 | 2.17% | |
| CRVS |
Corvus Pharmaceuticals, Inc.
Healthcare
|
Held | 7,165,006 | $107,045,189 | 2.07% | |
| AVBP |
ArriVent BioPharma, Inc.
Healthcare
|
Held | 3,027,328 | $105,169,374 | 2.03% | |
| ABVX |
Abivax S.A.
CALL
+ SHARES
Healthcare
|
Added | 746,522 | $99,481,521 | 1.92% | |
| GH |
Guardant Health, Inc.
Healthcare
|
Added | 583,700 | $87,572,511 | 1.69% | |
| ARGX |
Argenx SE
Healthcare
|
Reduced | 92,880 | $86,171,277 | 1.67% | |
| MRK |
Merck & Co., Inc.
Healthcare
|
Held | 663,400 | $85,246,900 | 1.65% | |
| QURE |
uniQure N.V.
Healthcare
|
Reduced | 1,807,486 | $83,252,805 | 1.61% | |
| PRAX |
Praxis Precision Medicines, Inc.
Healthcare
|
Added | 230,100 | $77,035,179 | 1.49% | |
| EW |
Edwards Lifesciences Corp
Healthcare
|
Reduced | 834,900 | $75,525,054 | 1.46% | |
| PRLD |
Prelude Therapeutics Inc
Healthcare
|
Added | 13,724,571 | $73,151,963 | 1.41% | |
| DYN |
Dyne Therapeutics, Inc.
Healthcare
|
Added | 3,235,684 | $71,864,541 | 1.39% | |
| NTRA |
Natera, Inc.
Healthcare
|
Held | 262,000 | $71,119,900 | 1.38% | |
| UNH |
Unitedhealth Group Inc
CALL
+ SHARES
Healthcare
|
NEW | 171,100 | $71,114,293 | 1.37% | |
| CGON |
CG Oncology, Inc.
Healthcare
|
Added | 972,800 | $69,117,440 | 1.34% | |
| SPRY |
ARS Pharmaceuticals, Inc.
Healthcare
|
Held | 8,288,510 | $66,390,965 | 1.28% | |
| ASND |
Ascendis Pharma A/S
Healthcare
|
Added | 244,456 | $65,201,304 | 1.26% | |
| HUM |
Humana Inc
Healthcare
|
NEW | 164,100 | $65,183,802 | 1.26% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Added | 1,681,300 | $65,066,310 | 1.26% | |
| BSX |
Boston Scientific Corp
Healthcare
|
Reduced | 1,483,200 | $63,302,976 | 1.22% | |
| ISRG |
Intuitive Surgical Inc
Healthcare
|
Reduced | 157,900 | $62,793,672 | 1.21% | |
| MLYS |
Mineralys Therapeutics, Inc.
Healthcare
|
Added | 2,110,300 | $56,935,894 | 1.10% | |
| ODTX |
Odyssey Therapeutics, Inc.
Healthcare
|
NEW | 3,001,198 | $56,152,414 | 1.09% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
Reduced | 892,471 | $53,869,549 | 1.04% | |
| ARQT |
Arcutis Biotherapeutics, Inc.
Healthcare
|
NEW | 2,042,000 | $53,541,240 | 1.04% | |
| BMY |
Bristol Myers Squibb Co
Healthcare
|
Held | 925,000 | $53,298,500 | 1.03% | |
| QTTB |
Q32 Bio Inc.
Healthcare
|
Added | 4,127,987 | $52,590,554 | 1.02% | |
| PVLA |
Palvella Therapeutics, Inc.
CALL
+ SHARES
Healthcare
|
Added | 332,360 | $50,791,255 | 0.98% | |
| SYK |
Stryker Corp
Healthcare
|
Reduced | 159,100 | $50,091,044 | 0.97% | |
| CAI |
Caris Life Sciences, Inc.
Healthcare
|
Held | 2,806,811 | $50,017,372 | 0.97% | |
| ELV |
Elevance Health, Inc.
CALL
+ SHARES
Healthcare
|
Added | 124,700 | $48,225,231 | 0.93% | |
| XBI |
State Street(R) SPDR(R) S&P(R) Biotech ETF
PUT
|
NEW | 300,000 | $47,475,000 | 0.92% | |
| TMO |
Thermo Fisher Scientific Inc.
Healthcare
|
Added | 90,700 | $45,473,352 | 0.88% | |
| STTK |
Shattuck Labs, Inc.
Healthcare
|
Held | 6,306,127 | $43,764,521 | 0.85% | |
| UPB |
Upstream Bio, Inc.
Healthcare
|
Held | 5,693,589 | $39,399,635 | 0.76% | |
|
|
Held | 999,000 | $37,382,580 | 0.72% | ||
| RYTM |
Rhythm Pharmaceuticals, Inc.
Healthcare
|
Added | 322,900 | $35,851,587 | 0.69% | |
| SNDX |
Syndax Pharmaceuticals Inc
Healthcare
|
Added | 1,542,000 | $33,708,120 | 0.65% | |
|
|
Added | 1,577,705 | $33,526,231 | 0.65% | ||
| CMPX |
Compass Therapeutics, Inc.
Healthcare
|
Held | 15,219,994 | $33,331,786 | 0.64% | |
| NKTR |
Nektar Therapeutics
Healthcare
|
Added | 465,346 | $32,485,804 | 0.63% | |
| KRYS |
Krystal Biotech, Inc.
Healthcare
|
Added | 83,200 | $30,922,944 | 0.60% | |
| AXSM |
Axsome Therapeutics, Inc.
Healthcare
|
Reduced | 117,578 | $28,779,567 | 0.56% | |
| KNSA |
Kiniksa Pharmaceuticals International, plc
Healthcare
|
Added | 420,600 | $26,897,370 | 0.52% |
Showing the top 50 of 117 positions. Create a free account to see every position, past quarters, search, filters and CSV export.
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.